Despite advancements in medical technology, early detection of PCa remains a significant challenge due to the limitations in specificity of current diagnostic methods, such as prostate-specific antigen (PSA) testing (Kalavacherla et al., 2023; Tikkinen et al., 2018). The gene discussed is KLK3; the disease is posterior cortical atrophy.